An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Read full text Summarise with VIRAT
Authors: Novartis
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Vivli
Publication date
27 March 2026
Language
EN
Document type
Dataset